Cargando…

Efficacy of Rubus coreanus Miq. and Astragalus membranaceus Bunge Extract for Postmenopausal Syndrome: A Randomised, Double-Blind, Placebo Comparative Clinical Trial

OBJECTIVES: The most effective way to improve menopausal symptoms is to supplement deficient oestrogen; however, long-term administration of synthetic oestrogen increases the risk for breast and uterine cancers. Here, we report results from a clinical trial of Rubus coreanus Miq. and Astragalus memb...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jeong-Su, Sung, Hyun Kyung, Kim, Seul-Ki, Lee, Hak Sung, Shin, Seon Mi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890844/
https://www.ncbi.nlm.nih.gov/pubmed/35251207
http://dx.doi.org/10.1155/2022/4066054
_version_ 1784661734999457792
author Park, Jeong-Su
Sung, Hyun Kyung
Kim, Seul-Ki
Lee, Hak Sung
Shin, Seon Mi
author_facet Park, Jeong-Su
Sung, Hyun Kyung
Kim, Seul-Ki
Lee, Hak Sung
Shin, Seon Mi
author_sort Park, Jeong-Su
collection PubMed
description OBJECTIVES: The most effective way to improve menopausal symptoms is to supplement deficient oestrogen; however, long-term administration of synthetic oestrogen increases the risk for breast and uterine cancers. Here, we report results from a clinical trial of Rubus coreanus Miq. and Astragalus membranaceus Bunge as agents for improving the menopause syndrome. METHODS: This study was a single-centre, double-blinded, parallel-group, placebo-controlled study. The efficacy of an extract of R. coreanus Miq. and A. membranaceus Bunge was investigated. Participants were females with postmenopausal syndrome in the menopausal or menopausal transition period. The primary endpoint of validation was improvement in the Kupperman index (KI) score of women. The secondary end point was change in the Menopause Rating Scale (MRS) and lipid profile. The participants were randomly allocated at a 1 : 1 ratio into R. coreanus Miq. and A. membranaceus Bunge extract (RCAM) or placebo groups and were administered 2000 mg of the extract or placebo, respectively, daily for 12 weeks. Outcomes were measured at visits 2 (day 0) and 5 (week 12). RESULTS: The RCAM group demonstrated decreased KI score and MRS compared with the placebo group after 12 weeks. In the safety evaluation, laboratory tests and vital signs demonstrated no clinically significant changes in subjects, and there was no difference in adverse reactions between the groups. The R. coreanus Miq. and A. membranaceus Bunge extract was effective in reducing postmenopausal symptoms in women. Moreover, the extract was found to be safe. CONCLUSIONS: For females with menopausal symptoms in the menopausal transitional and postmenopausal periods, ingestion of the R. coreanus Miq. and A. membranaceus Bunge extract for 12 weeks was effective, as demonstrated by a decrease in KI score and MRS relative to that in the placebo group, and significantly improved the menopausal symptoms.
format Online
Article
Text
id pubmed-8890844
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-88908442022-03-03 Efficacy of Rubus coreanus Miq. and Astragalus membranaceus Bunge Extract for Postmenopausal Syndrome: A Randomised, Double-Blind, Placebo Comparative Clinical Trial Park, Jeong-Su Sung, Hyun Kyung Kim, Seul-Ki Lee, Hak Sung Shin, Seon Mi Evid Based Complement Alternat Med Research Article OBJECTIVES: The most effective way to improve menopausal symptoms is to supplement deficient oestrogen; however, long-term administration of synthetic oestrogen increases the risk for breast and uterine cancers. Here, we report results from a clinical trial of Rubus coreanus Miq. and Astragalus membranaceus Bunge as agents for improving the menopause syndrome. METHODS: This study was a single-centre, double-blinded, parallel-group, placebo-controlled study. The efficacy of an extract of R. coreanus Miq. and A. membranaceus Bunge was investigated. Participants were females with postmenopausal syndrome in the menopausal or menopausal transition period. The primary endpoint of validation was improvement in the Kupperman index (KI) score of women. The secondary end point was change in the Menopause Rating Scale (MRS) and lipid profile. The participants were randomly allocated at a 1 : 1 ratio into R. coreanus Miq. and A. membranaceus Bunge extract (RCAM) or placebo groups and were administered 2000 mg of the extract or placebo, respectively, daily for 12 weeks. Outcomes were measured at visits 2 (day 0) and 5 (week 12). RESULTS: The RCAM group demonstrated decreased KI score and MRS compared with the placebo group after 12 weeks. In the safety evaluation, laboratory tests and vital signs demonstrated no clinically significant changes in subjects, and there was no difference in adverse reactions between the groups. The R. coreanus Miq. and A. membranaceus Bunge extract was effective in reducing postmenopausal symptoms in women. Moreover, the extract was found to be safe. CONCLUSIONS: For females with menopausal symptoms in the menopausal transitional and postmenopausal periods, ingestion of the R. coreanus Miq. and A. membranaceus Bunge extract for 12 weeks was effective, as demonstrated by a decrease in KI score and MRS relative to that in the placebo group, and significantly improved the menopausal symptoms. Hindawi 2022-02-23 /pmc/articles/PMC8890844/ /pubmed/35251207 http://dx.doi.org/10.1155/2022/4066054 Text en Copyright © 2022 Jeong-Su Park et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Park, Jeong-Su
Sung, Hyun Kyung
Kim, Seul-Ki
Lee, Hak Sung
Shin, Seon Mi
Efficacy of Rubus coreanus Miq. and Astragalus membranaceus Bunge Extract for Postmenopausal Syndrome: A Randomised, Double-Blind, Placebo Comparative Clinical Trial
title Efficacy of Rubus coreanus Miq. and Astragalus membranaceus Bunge Extract for Postmenopausal Syndrome: A Randomised, Double-Blind, Placebo Comparative Clinical Trial
title_full Efficacy of Rubus coreanus Miq. and Astragalus membranaceus Bunge Extract for Postmenopausal Syndrome: A Randomised, Double-Blind, Placebo Comparative Clinical Trial
title_fullStr Efficacy of Rubus coreanus Miq. and Astragalus membranaceus Bunge Extract for Postmenopausal Syndrome: A Randomised, Double-Blind, Placebo Comparative Clinical Trial
title_full_unstemmed Efficacy of Rubus coreanus Miq. and Astragalus membranaceus Bunge Extract for Postmenopausal Syndrome: A Randomised, Double-Blind, Placebo Comparative Clinical Trial
title_short Efficacy of Rubus coreanus Miq. and Astragalus membranaceus Bunge Extract for Postmenopausal Syndrome: A Randomised, Double-Blind, Placebo Comparative Clinical Trial
title_sort efficacy of rubus coreanus miq. and astragalus membranaceus bunge extract for postmenopausal syndrome: a randomised, double-blind, placebo comparative clinical trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890844/
https://www.ncbi.nlm.nih.gov/pubmed/35251207
http://dx.doi.org/10.1155/2022/4066054
work_keys_str_mv AT parkjeongsu efficacyofrubuscoreanusmiqandastragalusmembranaceusbungeextractforpostmenopausalsyndromearandomiseddoubleblindplacebocomparativeclinicaltrial
AT sunghyunkyung efficacyofrubuscoreanusmiqandastragalusmembranaceusbungeextractforpostmenopausalsyndromearandomiseddoubleblindplacebocomparativeclinicaltrial
AT kimseulki efficacyofrubuscoreanusmiqandastragalusmembranaceusbungeextractforpostmenopausalsyndromearandomiseddoubleblindplacebocomparativeclinicaltrial
AT leehaksung efficacyofrubuscoreanusmiqandastragalusmembranaceusbungeextractforpostmenopausalsyndromearandomiseddoubleblindplacebocomparativeclinicaltrial
AT shinseonmi efficacyofrubuscoreanusmiqandastragalusmembranaceusbungeextractforpostmenopausalsyndromearandomiseddoubleblindplacebocomparativeclinicaltrial